Polymorphic catechol-O-methyltransferase gene and breast cancer risk

We examined 483 Finnish breast cancer cases and 482 population controls to determine the potential effect of catechol- O -methyltransferase ( COMT ) genotype in individual susceptibility to breast cancer. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression after adjustment for known or suspected risk factors for breast cancer. When studied separately by menopausal status, the COMT-L allele-containing genotypes were inversely associated with premenopausal breast cancer, especially with advanced stage of the disease (OR, 0.44; 95% CI, 0.22–0.87). Among postmenopausal women a similar decreased risk was seen for local carcinoma associated with the COMT-LL genotype (OR, 0.55; 95% CI, 0.31–0.98). The lowest breast cancer risk was seen in the postmenopausal women with the COMT-LL genotype and low body-mass index (≤25.4 kg/m2; OR, 0.33; 95% CI, 0.13–0.83). Significantly increased risk, on the other hand, was seen for postmenopausal women with the COMT-LL genotype and long-term (>30 months) use of estrogen (OR, 4.02; 95% CI, 1.13–14.3), or with the COMT-L allele-containing genotypes and early age (≤12 years) at menarche (OR, 8.59; 95% CI, 1.85–39.8). Our study, therefore, suggests that the COMT genotype may define a portion of the individual breast cancer susceptibility that is associated with reproductive events and hormone exposure even if it does not seem to be a major overall risk factor for this malignancy.